Get a clear chart and learn what matters for safe use
Patients with unstable cardiovascular disease, poorly controlled hypertension, or significant hypotension may require additional monitoring or alternative therapies
An intramuscular injection is absorbed faster because the muscle tissue has more blood supply
It is not intended for human or animal consumption, medical use, cosmetic use, diagnostic use, therapeutic use, compounding, or resale as a finished drug product
Notably: BPC-157, KPV, MOTs-C, Emideltide (DSIP), Epitalon, Semax (heptapeptide) and TB-500 are among those expected to be reviewed in July 2026 Other substances, including Cathelicidin LL-37, Dihexa Acetate, PEG-MGF, GHK-Cu and Melanotan II, are under consideration for review by early 2027 Non-injectable GHK-Cu is following a slightly different path, with separate evaluation anticipated before February 2027